Mangner N, et al. - In this retrospective analysis of 598 consecutive patients, researchers assessed the influence of continued vs interrupted oral anticoagulation (OAC) on early safety, as well as the impact of postoperative anticoagulant management on 1-year mortality in patients with atrial fibrillation (AF) undergoing transfemoral transcatheter aortic valve implantation (TF-TAVI) for severe aortic stenosis (AS). Participants were categorized as interrupted (iVKA) vs continued vitamin K antagonist (cVKA) vs continued direct oral anticoagulants (DOAC) at the time of TF-TAVI. Baseline characteristics were equivalent among patients with iVKA (n=299), cVKA (n=117) and DOAC (n=182). No difference was found in the proportion of patients having a CHA₂DS₂-VASc-Score ≥3 and HAS-BLED-Score ≥3 between the groups. According to findings, the rate for the composite end point of early safety at 30 days was not increased with cVKA use. A significantly reduced rate of early safety endpoints at 30 days was observed in relation to use of a DOAC. In multivariate analysis, DOAC was found to be related to attenuated all-cause 1-year mortality while cVKA was comparable to iVKA.